The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Methamphetamine Psychosis: Epidemiology and Management
Open accessAbstract
Psychotic symptoms and syndromes are frequently experienced among individuals who use methamphetamine, with recent estimates of up to approximately 40 % of users affected. Although transient in a large proportion of users, acute symptoms can include agitation, violence, and delusions, and may require management in an inpatient psychiatric or other crisis intervention setting. In a subset of individuals, psychosis can recur and persist and may be difficult to distinguish from a primary psychotic disorder such as schizophrenia. Differential diagnosis of primary vs. substance-induced psychotic disorders among methamphetamine users is challenging; nevertheless, with careful assessment of the temporal relationship of symptoms to methamphetamine use, aided by state-of-the art psychodiagnostic assessment instruments and use of objective indicators of recent substance use (i.e., urine toxicology assays), coupled with collateral clinical data gathered from the family or others close to the individual, diagnostic accuracy can be optimized and the individual can be appropriately matched to a plan of treatment. The pharmacological treatment of acute methamphetamine-induced psychosis may include the use of antipsychotic medications as well as benzodiazepines, although symptoms may resolve without pharmacological treatment if the user is able to achieve a period of abstinence from methamphetamine. Importantly, psychosocial treatment for methamphetamine dependence has a strong evidence base and is the optimal first-line treatment approach to reducing rates of psychosis among individuals who use methamphetamines. Prevention of methamphetamine relapse is the most direct means of preventing recurrence of psychotic symptoms and syndromes. Long-term management of individuals presenting with recurrent and persistent psychosis, even in the absence of methamphetamine use, may include both behavioral treatment to prevent resumption of methamphetamine use and pharmacological treatment targeting psychotic symptoms. In addition, treatment of co-occurring psychiatric disorders including depression and anxiety is important as a means of preventing relapse to methamphetamine use, which is often triggered by associated symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For psychostimulant-induced psychosis, psychotic symptoms resolve with abstinence by about 1 week”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [80]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“whereas primary psychosis will require continued care with antipsychotic medication (80).”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [80]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“the standard of care for adolescent-and young adult SUD treatment is to use interventions that are specifically tailored or designed for their unique developmental stage.177,178,179”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [178]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Depression and quality of life in older persons: A review
Sivertsen, H., Bjørkløf, G. H., Engedal, K., Selbæk, G., & Helvik, A.-S. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000437299 · Cited by 14,152
Robins, L. N. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780290015001 · Cited by 5,219
Robins, L. N. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800360017003 · Cited by 2,909
Leucht, S., Pitschel‐Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 795
Provocative tests with psychostimulant drugs in schizophrenia
Lieberman, J. A., Kane, J. M., & Alvir, J. (1987) · Psychopharmacology · doi:10.1007/bf00216006 · Cited by 535
Courtney, K. E., & Ray, L. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.003 · Cited by 502
Addictions: A Comprehensive Guidebook
McCrady, B. S., & Epstein, E. E. (2013) · Cited by 488
Flagged first, then by citations
Research works printed but not linked: 6
- World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders. Geneva: Diagnostic Criteria For Research; 1992.
- Connell PH. Amphetamine psychosis. Maudsley Monograph No. 5, London: Oxford University Press; 1958.
- Volkow ND. NIDA research report: methamphetamine abuse and addiction. Washington: National Institute on Drug Abuse; 2006.
- Wada K, Fukui S. Residual symptoms in methamphetamine psychosis. J Mental Health. 1991;37:161–8.
- First MB, Spitzer RL, Williams JEW, et al. Structured Clinical Interview for DSM-IV-Clinician Version (SCID-CV) (User’s guide and interview). Washington, DC: American Psychiatric Press; 1997.
- Rawson RA. Methamphetamine: new knowledge, new treatments. Center City, MN: Hazelden; 2006.
Cited by
Sorted by citations
Items 201–266 of 266
Fataliyev, İ., Coşkun, M. N., Topcuoğlu, M., Erdogan, A. R., & Kulaksızoğlu, B. (2024) · Journal of Substance Use · doi:10.1080/14659891.2024.2446914 · Cited by 1
Drug Dependence Treatment Awareness among Japanese Female Stimulant Drug Offenders
Yatsugi, S., Fujita, K., Kashima, S., & Eboshida, A. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13111127 · Cited by 1
A new challenge for expert witnesses relying on subjective information
Fisher, B. A. J. (2017) · Forensic Sciences Research · doi:10.1080/20961790.2017.1342587 · Cited by 1
Predictors of Psychotic and Depressive Symptoms in Metamphetamine UsersPreprint
Karabulut, S. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4068671 · Cited by 1
Kuo, S.-C., Yeh, Y., Chen, C. Y., Huang, C. C., Shih, M.-C., Yen, C.-H., Ho, P. S., Liang, C., Tsou, C., Yang, B. Z., et al. (2018) · Neuropsychiatry · doi:10.4172/neuropsychiatry.1000448
Forensic Toxicology of Stimulants and Psychotropic Drugs
Nishiguchi, M., & Nishio, H. (2018) · Current human cell research and applications · doi:10.1007/978-981-13-2297-6_5
Methamphetamine psychosis: Lack of association with stimulant prescription ADHD medications
Mann, D. M., Marco, C. A., Detherage, J. P., Greene, P. J., & Ross, D. E. (2019) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2019.03.018
Vaisman‐Tzachor, R. (2019) · Open Access Journal of Addiction and Psychology · doi:10.33552/oajap.2019.01.000524
Explaining the Vampire Legend through Disease
Christner, C. J. (2019) · OpenSPACES@UNK
Methamphetamine-Related Psychiatric Symptoms with Special Reference to COVID-19 Issues
Yarema, M. V., & David, W. (2020) · Journal of Addiction Medicine and Therapeutic Science · doi:10.17352/2455-3484.000042
Anh, N. H., Trang, N. T., Diệp, N. B., Anh, V. M., Hiếu, T. T., Hòe, H. Đ., & Giang, L. M. (2021) · Tạp chí Nghiên cứu Y học · doi:10.52852/tcncyh.v138i2.78
Risicofactoren van psychotische symptomen en hun causaliteit: een overzicht
MEIRLAEN, J. W. (2021) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.77.21.119
Goudarzi, Z., Hoseini, S. E., Mehrabani, D., & HASHEMI, S. S. (2020) · PERIÓDICO TCHÊ QUÍMICA · doi:10.52571/ptq.v17.n36.2020.1163_periodico36_pgs_1147_1159.pdf
Hòe, H. Đ., Tran, K., Hai, N. V. B., Trang, P. T. H., & Liên, N. T. K. (2021) · Journal La Medihealtico · doi:10.37899/journallamedihealtico.v2i5.453
Luo, T., Xiao, M., Qi, C., Wu, Q., Tang, J., & Liao, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.786622
Psychiatric Issues in the Critically Poisoned Patient
Rasimas, J. J., & Carter, G. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-17900-1_44
Betzler, F., & Köhler, S. (2016) · Springer eBooks · doi:10.1007/978-3-642-55214-4_67-1
Tong, S., Zhou, S., Sun, S., Hong, L., Wang, C., Peng, C., Wei, J., Jiang, Y., He, H., & Zhao, K. (2022) · Research Square · doi:10.21203/rs.3.rs-1919400/v1
Prescription medication-induced psychosis: A high alert for drug experts
Taslim, N., & Edge, D. T. (2020) · Journal of Contemporary Pharmacy · doi:10.56770/jcp2020414
Ferreira, J. V., Chaves, G. A., Batista, M. A., Correia, L. C., de Souza, L. R., da Costa, D. C., Barcelos, M. P., da Silva, C. H. T. D. P., Taft, C. A., & Hage-Melim, L. I. D. S. (2022) · Engineering materials · doi:10.1007/978-3-031-07622-0_16
Juvonen, K. (2022) · Physician Assistant Clinics · doi:10.1016/j.cpha.2022.09.003
The Current Study and Potential Treatment of Drug Abuse
Liu, D. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/4/20220578
Valenzi, N. (2023) · Western Journal of Emergency Medicine · doi:10.5811/westjem.61594
Ureste, P. J., Gunther, M. G., Artz, J. D., & Wang, K. (2023) · Springer eBooks · doi:10.1007/978-3-031-14372-4_9
Enfoque diagnóstico y terapéutico de un primer episodio psicótico
de Antioquia, U., & Rosero, D. A. (2023) · doi:10.59473/medudea.pc.2023.13
Palis, H., & Macdonald, S. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.230266-f
Silva, C. J., Arrington‐Sanders, R., Goldstein, Z. G., Deutsch, M. B., Asupoto, O., Wurcel, A. G., Imbert, E., Hickey, M. D., Davids, A., Carvalho, A., et al. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197679098.003.0012
จิระการณ์, เ., & กัลยาศิริ, ร. (2017) · doi:10.58837/chula.the.2017.1538
Disorders Due to Substance Use: Stimulants
Sevarino, K. A., & Farrell, M. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_26-1
Toxic psychosis and its clinical significance
Semančíková, I., Kopeček, M., & Bezdíček, O. (2024) · Psychiatrie pro praxi · doi:10.36290/psy.2024.011
Impulse control disorders due to cocaine and synthetic stimulants use: a systematic review
Fedotov, I. A., Shustov, D. I., Petrov, D. S., Radostina, A. A., & Volkova, A. (2024) · Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery) · doi:10.33920/med-01-2405-09
Addressing methamphetamine use in persons with HIV
Martínez, E., & Dorfman, D. (2024) · AIDS · doi:10.1097/qad.0000000000003998
Guliyev, C., Aldemir, E., Şimşek, M., & Ögel, K. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2428242
Örüm, D., & Atmaca, M. (2025) · Medical Records · doi:10.37990/medr.1588069
Ansar, M., Gulshan, S., Shaikh, I. H., & Usman, M. (2024) · Journal of Health and Rehabilitation Research · doi:10.61919/jhrr.v4i3.1592
A genome-wide association study of methamphetamine use among people with HIV
Venkataraman, A., Jia, T., Ruderman, S., Haas, C., Nance, R., Mixson, L., Mayer, K., Saag, M., Chander, G., Moore, R., et al. (2025) · BMC Medical Genomics · doi:10.1186/s12920-025-02105-8
Bach, P., Foll, B. L., Davidson, S., de Kiewit, A., Bakouni, H., Poulin, G., Ghosh, M., & Jutras‐Aswad, D. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.107916
Bahceci, D., Siefried, K. J., Steele, M., Harrod, M., Bell, G., Barratt, M. J., Nicholas, C. R. N., Rodgers, A., Hendricks, P. S., Stauffer, C. S., et al. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112699 · Cited by 1
Seltzer, J. A., Guedez, H. M., Srihari, P., Clark, R. F., & Castillo, E. M. (2025) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2025.04.002
A polyunsaturated fatty acid (PUFA) theory of schizophrenia
Rappoport, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-44-345008-2.00009-6
Silva, C. J., Arrington‐Sanders, R., Goldstein, Z. G., Imbert, E., Hickey, M. D., Asupoto, O., Wurcel, A. G., Davids, A., Carvalho, A., García, D., et al. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197812631.003.0010
Shin, E., Chung, Y. H., Nguyen, B. T., Sharma, N., Tran, N. K. C., Nguyen, Y. N. D., Park, J. H., Kim, D.-J., Nabeshima, T., Jeong, J. H., et al. (2025) · Free Radical Research · doi:10.1080/10715762.2025.2551032
Khosroshahi, M. A., Farrokhi, A., & Soltanzadeh, H. (2025) · Addiction and Health · doi:10.34172/ahj.1484
Galhenage, J., Isuru, A., Dayabandara, M., & Hanwella, R. (2026) · Indian Journal of Psychological Medicine · doi:10.1177/02537176261451022
Hussein, H. K., Loarce, Y., & Barbaro, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.05.686833
Chen, L., Cassoday, S. L., Mamede, J. I., Al‐Harthi, L., & Hu, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1691165
Kampman, K. M. (2025) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894550862.lg06
Burrows, K., McNaughton, B. A., Yakshin, A. K., Coussa, V., Kuplicki, R., Aupperle, R. L., Savitz, J. B., Paulus, M. P., Stewart, J. L., & Figueroa‐Hall, L. K. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106261
Addictions: Everyone, everywhere, everything
Hoang, L., & Judd, S. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009335874.016
Zhang, H., Yu, Z., Fu, Q., Yang, J., Yan, M., & Hu, Z. (2026) · Scientific Reports · doi:10.1038/s41598-026-46389-x
Identification of distinct stimulant use trajectories and patterns of overdose
Shaw, L. C., Li, Y., Noguchi, J. E., Park, C. J., Biello, K. B., Hadland, S. E., Sherman, S. G., Macmadu, A., & Marshall, B. D. L. (2026) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2026.100709
Ruedisueli, I., Marienfeld, C. B., Tiefenthaler, C. M., Lee, A., Vera, A., Strathdee, S. A., & Friedman, J. R. (2026) · Harm Reduction Journal · doi:10.1186/s12954-026-01475-1
Limited Use, Lasting Consequences: Residual Psychosis and Recovery after Methamphetamine Use
Gautam, P., Rajbhandari, S., & Hamilton, T. (2025) · Archives of Trauma and Emergency Medicine · doi:10.33696/trauma.1.002
Bonenti, B., Kerswell, N. L., Shuttleworth, G., Dellosa, G., Barnett, A., Ahmadinejad, B., & Piatkowski, T. M. (2026) · Journal of Dual Diagnosis · doi:10.1080/15504263.2026.2686090
Stimulants: Cocaine, Amphetamines, and Other Stimulants
DeVido, J. J. (2026) · Springer eBooks · doi:10.1007/978-3-032-24174-0_12
Kadyrov, A. (2026) · Ukrains kyi Visnyk Psykhonevrolohii · doi:10.36927/2079-0325-v34-is2-2026-13
Shah, M. A., Zaman, S., Khattak, A. Z., & Zaman, M. Z. (2026) · Journal of Substance Use · doi:10.1080/14659891.2026.2698558
Zito, M. F., Wright, H. M., Gabrielian, S. E., Marder, S. R., & Mooney, L. J. (2026) · Substance Use & Addiction Journal · doi:10.1177/29767342261467612
Self-citationShi, S., Su, H., Sun, Y., Zhong, N., Jiang, H., Du, J., Chen, T., & Zhao, M. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117407
Kordi, N., Saydi, A., Kheirandish, R., Karami, S., Gentil, P., & Saghari, S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0356103
Care Navigation for Methamphetamine Use Disorder
Al‐Tayyib, A., Rinehart, D. J., Duarte, K. G., Gilbert, A., Newton, C., Loh, R. M., Bacon, E., & Simpson, S. A. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.31628
Seeley, S. L., Snyder, M., & D’Souza, M. S. (2026) · Behavioural Brain Research · doi:10.1016/j.bbr.2026.116530
Li, Y., Yang, B., Zhang, H., Yu, Q., Zou, Q., Wan, Y., & Zhao, D. (2026) · Research Square · doi:10.21203/rs.3.rs-11238606/v1
Emergency Management of Cocaine & Amphetamine Overdose is Important
Draghmeh, K., Gold, M. S., Fuehrlein, B., & Hicks, A. (2026) · Current Addiction Reports · doi:10.1007/s40429-026-00799-z
Metadata
- Authors
- Glasner-Edwards, S., & Mooney, L. J.
- Affiliations
- University of California, Los Angeles (US)
- ORCID
- Mooney, Larissa J.
- Venue
- CNS Drugs
- Published
- 2014-11-06
- Volume
- 28
- Issue
- 12
- Pages
- 1115-1126
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC5027896
- OpenAlex
- W2035893127
- Cited by
- 266
- References
- 97
- Citations by year
- 2026: 26 · 2025: 28 · 2024: 29 · 2023: 34 · 2022: 31 · 2021: 31 · 2020: 18 · 2019: 19 · 2018: 26 · 2017: 9 · 2016: 12 · 2015: 2 · 2014: 1
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (K23DA020085)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- methamphetamine psychosis, drug-induced psychosis, differential diagnosis, schizophrenia, antipsychotic drugs, benzodiazepines, methamphetamine dependence, psychosocial interventions, relapse prevention, urine toxicology, crisis intervention
- MeSH terms
- Central Nervous System Stimulants, Humans, Methamphetamine, Psychoses, Substance-Induced
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
